Drug Type Synthetic peptide |
Synonyms- |
Action- |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), HER2 inhibitors(Receptor protein-tyrosine kinase erbB-2 inhibitors), VEGFR2 inhibitors(Vascular endothelial growth factor receptor 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseDiscovery |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Discovery | - | 21 Oct 2022 |